ANNX — Annexin Pharmaceuticals AB (publ) Income Statement
0.000.00%
Last trade - 00:00
- SEK309.13m
- SEK271.78m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 28.3 | 43.7 | 51.2 | 40.7 | 44.2 |
Operating Profit | -28.3 | -43.7 | -51.2 | -40.7 | -44.2 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -28.4 | -44.2 | -52.1 | -40.7 | -44.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -28.4 | -44.2 | -52.1 | -40.7 | -44.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -28.4 | -44.2 | -52.1 | -40.7 | -44.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -28.4 | -44.2 | -52.1 | -40.7 | -44.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.535 | -0.362 | -0.36 | -0.158 | -0.247 |
Dividends per Share |